Tarik Asselah

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

Medicine, Internal Medicine, Pharmacology +8

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

Jordan J. Feld, Ira M. Jacobson, Christophe Hézode et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

Graham R. Foster, Nezam H. Afdhal, Stuart K. Roberts et al. · New England Journal of Medicine · 2015 · 850 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

Fabrice Carrat, Hélène Fontaine, Céline Dorival et al. · The Lancet · 2019 · 631 citations · Full text

Pharmacy, Pharmacotherapy, Outcomes Research +13